Spectranetics Corporation to Present at CCBN Virtual Healthcare Conference.Business Editors/Medical Writers CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network Virtual Healthcare Conference COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Dec. 5, 2002 Spectranetics Corporation (Nasdaq:SPNC SPNC South Peel Naturalists' Club (Canada) SPNC Socialist Party of North Carolina SPNC Sales Price Net of total seller paid Concessions (real estate) ) - today announced that it will be presenting at the CCBN Virtual Healthcare Conference on Tuesday, December 10, 2002, at 4:30 p.m. Eastern (1:30 p.m. Pacific). Emile J. Geisenheimer, chairman of the board and acting chief executive officer of Spectranetics, will present during the live webcast and take questions from participants. Interested investors can access the presentation from CCBN's Investor Distribution Network to both institutional and individual investors. Individual investor can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the webcast via CCBN's password protected event management site, StreetEvents, at www.streetevents.com. Spectranetics is a medical device company that develops, manufactures and markets a proprietary excimer laser system and related accessory products for use in minimally invasive surgical procedures within the cardiovascular system. The company's CVX-300(R) excimer laser is the only system approved by the Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for multiple cardiovascular procedures, including coronary atherectomy, the treatment of in-stent restenosis prior to radiation therapy and the removal of problematic pacemaker and defibrillator defibrillator, device that delivers an electrical shock to the heart in order to stop certain forms of rapid heart rhythm disturbances (arrhythmias). The shock changes a fibrillation to an organized rhythm or changes a very rapid and ineffective cardiac rhythm to a leads. The company is currently conducting two investigational trials designed to obtain FDA approval to market products in the United States for additional applications. The LACI LACI Cardiology 1 A clinical trail–Laser Angioplasty for Critical Ischemia 2 Lipoprotein-associated coagulation inhibitor, aka Tissue factor pathway inhibitor, see there (Laser Angioplasty for Critical Ischemia) trial tests laser atherectomy to improve circulation to the lower leg. The PELA (Peripheral Excimer Laser Angioplasty peripheral excimer laser angioplasty See PELA. ) trial deals with blockages in arteries in the upper leg. Nearly all of the company's FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. Spectranetics received regulatory approval from the Ministry of Health and Welfare The Ministry of Health and Welfare is a branch of the government of South Korea. External links
• • to market its laser and various sizes of its Extreme(R) and Vitesse(R) C coronary catheters in Japan in October of 2001, and is currently pursuing reimbursement approval there. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion